Evidence map›Paper›PMID 42127219›Full record

ArticleScience translational medicine2026

RNA-LNP-mediated in vivo prime editing corrects disease phenotypes in a mouse model of citrullinemia type I.

András Tálas, Eleonora I Ioannidi, Yanik Weber, Tatjana Haenggi, Péter István Kulcsár, Nadia Zürcher, Erica Faccin, Woohyun J Moon, Lucas Kissling, Elina Andrea Villiger and 13 more

Abstract read
In one paragraph

Article in Science translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

András TálasInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.ORCID 0000-0003-0851-8333
Eleonora I IoannidiInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.
Yanik WeberInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-0914-8541
Tatjana HaenggiInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.ORCID 0000-0001-6285-2602
Péter István KulcsárInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.
Nadia ZürcherDivision of Metabolism and Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland.
Erica FaccinDivision of Metabolism and Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland.ORCID 0009-0006-5589-5798
Woohyun J MoonAcuitas Therapeutics Inc., Vancouver, BC, Canada.ORCID 0009-0001-1395-823X
Lucas KisslingInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-4989-0695
Elina Andrea VilligerInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.ORCID 0009-0002-3454-9045
Mai MatsushitaDepartment of Biology, Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland.ORCID 0000-0001-5693-461X
Tanja RothganglInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.
Sharan JanjuhaInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.
Paulo J C LinAcuitas Therapeutics Inc., Vancouver, BC, Canada.ORCID 0000-0002-9310-1366
Martin PomsDivision of Clinical Chemistry and Biochemistry, University Children's Hospital Zurich, Zurich, Switzerland.ORCID 0000-0002-4426-314X
Hiromi MuramatsuDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0003-1544-1493
Máté VadovicsDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0001-9028-987X
Andreas ReichmuthInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-4365-2119
Manfred KopfDepartment of Biology, Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland.ORCID 0000-0002-0628-7140
Norbert PardiDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0003-1008-6242
Ying K TamAcuitas Therapeutics Inc., Vancouver, BC, Canada.ORCID 0000-0002-4083-5251
Johannes HäberleDivision of Metabolism and Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland.ORCID 0000-0003-0635-091X
Gerald SchwankInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.ORCID 0000-0003-0767-2953

Funding

Translational Immunology CoreU19AI181968 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI LIU, CHANG C · 2024 to 2024
$33.1M
Lipid nanoparticles as novel adjuvants inducing effective T follicular helper cell and humoral immune responsesR01AI153064 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Michela Locci, Norbert Pardi · 2020 to 2026
$4.2M
NIAID NIH HHS R01 AI153064NIAID NIH HHS U19 AI181968
6 · The paper itself

Abstract

Citrullinemia type I (CTLN1) is a severe urea cycle disorder caused by pathogenic variants in the

Indexed as

CitrullinemiaGene EditingLipidsNanoparticlesAnimalsArgininosuccinate SynthaseCitrullineDependovirusDisease Models, AnimalHepatocytesHumansLiverMiceMutationPhenotypeArgininosuccinate SynthaseCitrullineLipids

Identifiers

PMID42127219
PMCPMC7619498

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.